Literature DB >> 11755503

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.

R S Legro1, A R Kunselman, A Dunaif.   

Abstract

PURPOSE: Women with polycystic ovary syndrome are hyperandrogenemic and insulin resistant, which are associated with alterations in circulating lipid and lipoprotein levels. We sought to determine the prevalence of, and risk factors for, lipid abnormalities in these women. SUBJECTS AND METHODS: Non-Hispanic white women with polycystic ovary syndrome (n = 195) and ethnically matched control women (n = 62) had fasting blood obtained for hormone and lipid levels. Subjects were categorized by body mass index (nonobese <27 kg/m(2), obese > or =27 kg/m(2)), and analyses were adjusted for age.
RESULTS: Total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels increased significantly in obese women with polycystic ovary syndrome (n = 153) compared with obese control women (n = 35; mean difference in total cholesterol level = 29 mg/dL; 95% confidence interval [CI]: 14 to 45 mg/dL; P <0.001; mean difference in LDL-C level = 16 mg/dL; 95% CI: 4 to 30 mg/dL; P = 0.006). Similarly, total cholesterol and LDL-C levels increased significantly in nonobese women with polycystic ovary syndrome (n = 42) compared with nonobese control women (n = 27; mean difference in total cholesterol = 32 mg/dL; 95% CI: 13 to 52 mg/dL; P <0.001; mean difference in LDL-C level = 32 mg/dL; 95% CI: 15 to 52 mg/dL; P <0.001). In obese women, high-density lipoprotein cholesterol (HDL-C) and triglyceride levels increased significantly in women with polycystic ovary syndrome compared with control women (mean difference in HDL-C level = 6 mg/dL; 95% CI: 2 to 12 mg/dL; P = 0.002; mean difference in triglyceride level = 34 mg/dL; 95% CI: 1 to 77 mg/dL; P = 0.04). Differences in LDL-C and HDL-C levels, but not triglyceride levels, remained significant after adjusting for alcohol intake, smoking, and exercise. Although age, body mass index, and polycystic ovary syndrome status were significant predictors of lipid levels, these factors accounted for no more than 25% of the variance.
CONCLUSIONS: In this large study of non-Hispanic white women, elevations in LDL-C levels were the predominant lipid abnormality in women with polycystic ovary syndrome, independent of obesity. The characteristic dyslipidemia of insulin resistance was absent. Indeed, obese women with polycystic ovary syndrome had relatively elevated HDL-C levels, which may confer some protection against cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11755503     DOI: 10.1016/s0002-9343(01)00948-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  145 in total

1.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

Authors:  Susan Sam; David A Ehrmann
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

2.  Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome.

Authors:  Susan Sam; Richard S Legro; Paulina A Essah; Teimuraz Apridonidze; Andrea Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

3.  Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome.

Authors:  M Rizzo; R A Longo; E Guastella; G B Rini; E Carmina
Journal:  J Endocrinol Invest       Date:  2010-10-15       Impact factor: 4.256

4.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

5.  Lipid profile in relation to anthropometric indices and insulin resistance in overweight women with polycystic ovary syndrome.

Authors:  Maryam Saghafi-Asl; Saeed Pirouzpanah; Mehranghiz Ebrahimi-Mameghani; Mohammad Asghari-Jafarabadi; Soudabeh Aliashrafi; Bita Sadein
Journal:  Health Promot Perspect       Date:  2013-12-31

6.  Effects of low-dose metformin in Japanese women with clomiphene-resistant polycystic ovary syndrome.

Authors:  Takumi Kurabayashi; Mina Suzuki; Katsunori Kashima; Junichi Banzai; Kyoko Terabayashi; Kazuyuki Fujita; Kenichi Tanaka
Journal:  Reprod Med Biol       Date:  2004-03-30

7.  Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.

Authors:  H F Escobar-Morreale; G Villuendas; J I Botella-Carretero; J Sancho; J L San Millán
Journal:  Diabetologia       Date:  2003-05-09       Impact factor: 10.122

Review 8.  Oligomenorrhoea in exercising women: a polycystic ovarian syndrome phenotype or distinct entity?

Authors:  Susan Awdishu; Nancy I Williams; Sheila E Laredo; Mary Jane De Souza
Journal:  Sports Med       Date:  2009       Impact factor: 11.136

9.  Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives.

Authors:  Richard S Legro; Rebecca L Roller; William C Dodson; Christina M Stetter; Allen R Kunselman; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

10.  Comparison of metabolic and obesity biomarkers between adolescent and adult women with polycystic ovary syndrome.

Authors:  Sebastião Freitas de Medeiros; Matheus Antônio Souto de Medeiros; Bruna Barcelo Barbosa; Márcia Marly Winck Yamamoto; Gustavo Arantes Rosa Maciel
Journal:  Arch Gynecol Obstet       Date:  2020-11-17       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.